Breaks Categories: News

MondayMay 18, 2026 9:20 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2…

Continue Reading

FridayMay 15, 2026 1:21 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Subsidiary Active Intelligence to Showcase Wellness Products at ECRM Conference 

Nutriband (NASDAQ: NTRB) announced that its wholly owned subsidiary, Active Intelligence, will participate in the June 2026 ECRM conference, where it plans to showcase its expanding portfolio of wellness, recovery and performance-focused consumer products to buyers from major retail, pharmacy and healthcare organizations. The company will feature its existing AI Tape line and introduce new products including AI Performance Tape, AI Energy Patches and AI Sleep as it seeks to expand retail partnerships and distribution opportunities. To view the full press release, visit https://ibn.fm/MdpEg About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent…

Continue Reading

FridayMay 15, 2026 12:05 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in NetworkNewsAudio Editorial on Voice-Based Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.  MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in a NetworkNewsAudio audio press release highlighting the emerging potential of AI-powered voice analysis as a noninvasive method for intoxication detection. The editorial explores how speech-based diagnostics may offer rapid, real-time assessment of cognitive and physiological impairment by analyzing measurable vocal biomarkers such as tone, pitch, rhythm and articulation. To view the full press release, visit https://ibn.fm/KxB4E About MindBio Therapeutics Corp. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to…

Continue Reading

FridayMay 15, 2026 11:53 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio audio press release focused on emerging opportunities in central nervous system drug delivery, highlighting the challenges posed by the blood-brain barrier and the company’s efforts to advance technologies designed to overcome those limitations. The editorial also noted Oncotelic’s recent strategic monetization agreement with Lunai Bioworks involving its N2B delivery system, supporting initiatives in biodefense and Alzheimer’s disease treatment. To view the full press release, visit https://ibn.fm/ySesO About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic…

Continue Reading

FridayMay 15, 2026 10:30 am

BioMedNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio audio press release examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability. To view the full press release, visit https://ibn.fm/wsiDy About SureNano Science Ltd. SureNano Science Ltd. (CSE:…

Continue Reading

FridayMay 15, 2026 10:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports First-Quarter Results, Highlights Progress Across Biotech Platform

Oncotelic Therapeutics (OTCQB: OTLC) reported first-quarter 2026 financial results and a corporate update highlighting continued advancement across its oncology, AI-enabled drug development and advanced drug delivery initiatives, including progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform. The company also said it maintained the previously established approximately $388 million fair value of its 45% ownership interest in GMP Biotechnology as of March 31, 2026, while continuing to pursue capital-efficient growth across its diversified biotechnology platform. To view the full press release, visit https://ibn.fm/DTVsF About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

Continue Reading

ThursdayMay 14, 2026 11:36 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies addressing challenges in Alzheimer’s disease and biodefense research. The editorial highlights the company’s proprietary intranasal nose-to-brain delivery platform, designed to bypass the blood-brain barrier and enable direct therapeutic delivery to the central nervous system, reflecting growing interest in advanced drug delivery approaches for neurological treatment. To view the full press release, visit https://ibn.fm/aSsCf About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage…

Continue Reading

ThursdayMay 14, 2026 11:27 am

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Emerging GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its featured placement in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the treatment of obesity, type 2 diabetes and related metabolic conditions. To view the full press release, visit https://ibn.fm/9zCgz About SureNano Science Ltd. SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing…

Continue Reading

ThursdayMay 14, 2026 10:00 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in BioMedWire Editorial on Real-Time Intoxication Detection Technologies

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced its featured placement in an editorial published by BioMedWire, highlighting emerging opportunities in real-time intoxication detection technologies. The editorial spotlights MindBio’s AI-driven voice analysis platform, which is being developed to detect impairment from brief speech recordings across a range of substances, addressing growing demand for faster, noninvasive and scalable intoxication detection solutions across healthcare, workplace safety and public health applications. To view the full press release, visit https://ibn.fm/1WCqA About MindBio Therapeutics Corp. MindBio is a…

Continue Reading

ThursdayMay 14, 2026 9:50 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage neurology and oncology assets. Following quarter end, the company strengthened its balance sheet with a $22.5 million private placement, which, together with existing cash, is expected to support operations beyond 12 months as CNS pursues asset acquisitions and explores out-licensing opportunities for its legacy glioblastoma programs. To view the full press release, visit https://ibn.fm/HP5Xy About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive…

Continue Reading